2-methoxycarbonylmethyl-5-nitro-benzoic acid methyl ester | 64481-28-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methoxycarbonylmethyl-5-nitro-benzoic acid methyl ester
• 英文别名: methyl 2-(2-methoxy-2-oxoethyl)-5-nitrobenzoate；(2-methoxycarbonyl-4-nitro-phenyl)-acetic acid methyl ester；(2-Methoxycarbonyl-4-nitro-phenyl)-essigsaeure-methylester；4-Nitrohomophthalsaeuredimethylester
• CAS: 64481-28-3
• 化学式: C₁₁H₁₁NO₆
• 分子量: 253.211
• InChiKey: YLFLCTBGQLPNCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  98.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-methoxycarbonylmethyl-5-nitro-benzoic acid methyl ester 在 sodium acetate 作用下， 生成 6-nitro-4-oxo-3-phenyl-3,4-dihydro-phthalazine-1-carboxylic acid
  参考文献：
  名称：

  Borsche; Diacont, Justus Liebigs Annalen der Chemie, 1934, vol. 510, p. 287,295

  摘要：

  DOI：
• 作为产物：
  描述：

  6-硝基-1-茚满酮 在 chromium(III) oxide 、 五氯化磷 、 硫酸 作用下， 生成 2-methoxycarbonylmethyl-5-nitro-benzoic acid methyl ester
  参考文献：
  名称：

  Ingold; Piggott, Journal of the Chemical Society, 1923, vol. 123, p. 1482,1508

  摘要：

  DOI：

文献信息

• HCV Protease Inhibitors
  申请人：Shanghai Tangrun Pharmaceuticals, Co., Ltd.

  公开号：US20140163219A1

  公开（公告）日：2014-06-12

  A compound of general formula (I); A is O, S, CH, NH or NR′, when O links with Z 3 , Z 1 is N or CR Z1 , Z 2 is CR Z2 , when Z 1 links with O, Z 2 is CH, Z 3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y 1 —R m ; A 1 is NH or CH 2 ; R 1 ′ is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A 2 is N, O or linking bond; R 1 is hydrogen, or, R 1 linking covalently with R 3 forms C 5 -C 9 saturated or unsaturated hydrocarbon chain substituted by O or N; R 3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R 4 is alkoxy-CO, alkyl-NHCO, (alkyl) 2 NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.

  通用式(I)的化合物；A为O、S、CH、NH或NR′，当O与Z3连接时，Z1为N或CRZ1，Z2为CRZ2，当Z1与O连接时，Z2为CH，Z3为C—Ar；Ra、Rb、Rc和Rd独立地为H、OH、卤素或—Y1—Rm；A1为NH或CH2；R1′为烷基、芳基、环烷基、杂环烷基或杂芳基；A2为N、O或连接键；R1为氢，或者R1与R3共价连接形成由O或N取代的C5-C9饱和或不饱和碳氢链；R3为烷基、环烷基、杂环烷基、烷基取代的环烷基等；R4为烷氧基-CO、烷基-NHCO、(烷基)2NCO，或者被芳基、环烷基、杂环烷基取代的甲酰基。
• A new method using 1,3,5-triazine as an umpolung hydrogen cyanide equivalent toward the syntheses of isoquinolinone and 2-pyridone derivatives
  作者：Joji Hayashida、Shinya Yoshida

  DOI：10.1016/j.tetlet.2018.09.029

  日期：2018.10

  expansion of the synthetic application of 1,3,5-triazine as an umpolung hydrogen cyanide equivalent. The reaction proceeded under mild conditions to provide various isoquinolinone and 2-pyridone derivatives with excellent yields.

  对Hermecz和Hartenstein的环化方法进行了研究。克服了有限的底物范围，从而扩展了1,3,5-三嗪作为umpolung氰化氢等价物的合成应用。反应在温和的条件下进行，以优异的产率提供了各种异喹啉酮和2-吡啶酮衍生物。
• Substituted indolinones
  申请人：——

  公开号：US20030092756A1

  公开（公告）日：2003-05-15

  The present invention relates to indolinones substituted in the 6-position of general formula 1 wherein R 1 to R 5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一种通式1中6位取代的吲哚酮，其中R1至R5和X的定义如权利要求1中定义的，其异构体和盐，特别是具有有价值的药理特性的生理上可接受的盐，特别是对各种受体酪氨酸激酶和细胞周期蛋白/CDK复合物以及内皮细胞增殖具有抑制作用的物质，含有这些化合物的药物组合物，其用途和制备这些化合物的方法。
• Polycyclic and heterocyclic chromophores for bis-imide tumoricidals
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05416089A1

  公开（公告）日：1995-05-16

  Anticancer compounds of formula I: ##STR1## and pharmaceutically acceptable salts thereof, wherein: R.sup.1, R.sup.2 and R.sup.3 are independently selected H, CH.sub.3, NH.sub.2, NO.sub.2, and CN; R.sup.9 and R.sup.10 are H or alkyl or halo, X.sup.1 and Y.sup.1 or X.sup.2 and Y.sup.2, when present, join together to form, independently, a six membered 1N heterocycle substituted with 1-2 R.sup.3 ; or the group: ##STR2## wherein one of W or Z is C.dbd.O and the other is C.dbd.O, NH, S or O; or when X.sup.2 and Y.sup.2 are not joined together and when R.sup.2 is in the 4-position, then X.sup.2 and R.sup.2 may join together to form an ethylene bridge; are disclosed.

  公式I的抗癌化合物：##STR1##及其药学上可接受的盐，其中：R.sup.1、R.sup.2和R.sup.3独立选择H、CH.sub.3、NH.sub.2、NO.sub.2和CN；R.sup.9和R.sup.10为H或烷基或卤素，当存在X.sup.1和Y.sup.1或X.sup.2和Y.sup.2时，它们独立地结合在一起形成一个六元1N杂环，被1-2个R.sup.3取代；或者该基团：##STR2## 其中W或Z之一为C.dbd.O，另一个为C.dbd.O、NH、S或O；或者当X.sup.2和Y.sup.2没有结合在一起且R.sup.2在4位时，那么X.sup.2和R.sup.2可以结合在一起形成一个乙烯桥。
• HCV protease inhibitors
  申请人：Zhang Suoming

  公开号：US08969373B2

  公开（公告）日：2015-03-03

  A compound of general formula (I); A is O, S, CH, NH or NR′, when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y1—Rm; A1 is NH or CH2; R1′ is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.

  通式（I）的化合物；其中A为O、S、CH、NH或NR′，当O与Z3连接时，Z1为N或CRZ1，Z2为CRZ2，当Z1与O连接时，Z2为CH，Z3为C-Ar；Ra、Rb、Rc和Rd独立地为H、OH、卤素或-Y1-Rm；A1为NH或CH2；R1′为烷基、芳基、环烷基、杂环烷基或杂芳基；A2为N、O或连接键；R1为氢，或R1与R3共价连接形成由O或N取代的C5-C9饱和或不饱和碳氢链；R3为烷基、环烷基、杂环烷基、被环烷基取代的烷基等；R4为烷氧基-CO、烷基-NHCO、（烷基）2NCO或被芳基、环烷基、杂环烷基取代的甲酰基。